|
WO2011107583A1
|
|
Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
|
|
US2011257148A1
|
|
Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
|
|
EP2367788A1
|
|
3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
|
|
CN102224135A
|
|
Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
|
|
EP2271635A1
|
|
Modulators of dopamine neurotransmission
|
|
NZ588209A
|
|
1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives for the modulation of dopaminergic function in the central nervous system
|
|
CN102015674A
|
|
Modulators of dopamine neurotransmission
|
|
NZ581363A
|
|
New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
|
|
NZ581364A
|
|
Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
|
|
RU2470013C2
|
|
N-oxide and/or di-n-oxide derivatives of stabilisers/modulators of dopamine receptors, demonstrating improved profiles of cardio-vascular side effects
|
|
US2007179185A1
|
|
Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
|
|
EP1963268A1
|
|
Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
|
|
NZ555094A
|
|
Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
|
